Currently, immunotherapy targeting the PD-1/PDL1 pathway is one of the most effective therapeutic options, but its efficacy in PCC is unsatisfactory, partly due to the highly immunosuppressive state of PCC [63]. This evidence concerns the gene CD274 and adrenal gland pheochromocytoma.